{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:15Z","timestamp":1786982715425,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is an orphan disease characterized by excessive inflammation and poor outcome. We sought to further characterize clinical features, courses, and risk factors of secondary HLH (sHLH) triggered by infection (iHLH). 28 (43.1%) of 65 adult sHLH cases treated at our hospital from 2012\u20132024 were infection-associated. iHLH patients were mostly male (71.4%). Infectious agents most frequently detected were EBV (57.1%) and leishmania (14.3%). The median time to diagnosis was 13 [6.0;24.8] days. iHLH patients had a mortality rate of 39.3% (median follow-up time: 735 [336;1140] days), worse survival than patients with autoimmune-triggered (hazard ratio: 3.33 (1.01\u201311.10), p\u2009=\u20090.049), and better survival than patients with paraneoplastic HLH (hazard ratio: 0.19 (0.10\u20130.84), p\u2009=\u20090.002). Elevated levels of soluble interleukin-2 receptor (sIL2R;\u2009&gt;\u20096,000 I\/U), low thrombocyte counts (&lt;\u200940 G\/l), and a history of malignant disease were associated with adverse outcomes. Protracted time to diagnosis was associated with severe disease courses and with leishmaniosis. Further, sIL2R levels correlated positively with prolonged aPTT and thrombocytopenia, and hypertriglyceridemia with elevated INRs. Patients with an elevated sIL2R:ferritin ratio were more likely to have a history of malignant comorbidities. Taken together, sIL2R, thrombocytopenia, and a history of malignant disease are important prognostic factors of iHLH. Patients with high sIL2R levels or hypertriglyceridemia may be at higher risk of bleeding, and patients with elevated sIL2R:ferritin ratios should be assessed for possible malignant comorbidities. Lastly, increased awareness of the disease and newly emerging pathogens (i.e. leishmania) may shorten the time to diagnosis, and thus reduce severe courses of iHLH.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s15010-025-02559-z","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:53:16Z","timestamp":1748361196000},"page":"2135-2147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical features, course, and risk factors of infection-associated secondary hemophagocytic lymphohistiocytosis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-1070","authenticated-orcid":false,"given":"Michael","family":"Ruzicka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-4753","authenticated-orcid":false,"given":"Thomas","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-8555","authenticated-orcid":false,"given":"Hans-Joachim","family":"Stemmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-1020","authenticated-orcid":false,"given":"Stephanie-Susanne","family":"Stecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9644-2003","authenticated-orcid":false,"given":"Fabian","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-052X","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-4957","authenticated-orcid":false,"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"4","key":"2559_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1651-2227.1991.tb11878.x","volume":"80","author":"JI Henter","year":"1991","unstructured":"Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80(4):428\u201335. https:\/\/doi.org\/10.1111\/j.1651-2227.1991.tb11878.x.","journal-title":"Acta Paediatr Scand"},{"issue":"11","key":"2559_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000797","volume":"6","author":"J West","year":"2022","unstructured":"West J, Stilwell P, Liu H, Ban L, Bythell M, Card TR, et al. Temporal trends in the incidence of hemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003\u20132018. Hemasphere. 2022;6(11): e797. https:\/\/doi.org\/10.1097\/HS9.0000000000000797.","journal-title":"Hemasphere"},{"issue":"2","key":"2559_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bjh.18617","volume":"201","author":"D Kuron","year":"2023","unstructured":"Kuron D, Voran JC, von Samson-Himmelstjerna FA, Baldus C, Kunzendorf U, Schulte K, et al. Epidemiology of haemophagocytic lymphohistiocytosis at the population level in Germany. Br J Haematol. 2023;201(2):285\u20139. https:\/\/doi.org\/10.1111\/bjh.18617.","journal-title":"Br J Haematol"},{"key":"2559_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.03.023","volume":"114","author":"R Machowicz","year":"2017","unstructured":"Machowicz R, Janka G, Wiktor-Jedrzejczak W. Similar but not the same: differential diagnosis of HLH and sepsis. Crit Rev Oncol Hematol. 2017;114:1\u201312. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.023.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2559_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u201331. https:\/\/doi.org\/10.1002\/pbc.21039.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2559_CR6","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613\u201320. https:\/\/doi.org\/10.1002\/art.38690.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"2559_CR7","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood.2021012764","volume":"139","author":"A Zoref-Lorenz","year":"2022","unstructured":"Zoref-Lorenz A, Murakami J, Hofstetter L, Iyer S, Alotaibi AS, Mohamed SF, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022;139(7):1098\u2013110. https:\/\/doi.org\/10.1182\/blood.2021012764.","journal-title":"Blood"},{"issue":"7","key":"2559_CR8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1182\/blood.2021014675","volume":"139","author":"P La Rosee","year":"2022","unstructured":"La Rosee P. Detecting HLH in hematologic malignancies. Blood. 2022;139(7):961\u20133. https:\/\/doi.org\/10.1182\/blood.2021014675.","journal-title":"Blood"},{"issue":"5","key":"2559_CR9","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","volume":"6","author":"S Ehl","year":"2018","unstructured":"Ehl S, Astigarraga I, von Bahr GT, Hines M, Horne A, Ishii E, et al. Recommendations for the use of etoposide-based therapy and bone marrow transplantation for the treatment of HLH: consensus statements by the HLH steering committee of the histiocyte society. J Allergy Clin Immunol Pract. 2018;6(5):1508\u201317. https:\/\/doi.org\/10.1016\/j.jaip.2018.05.031.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"25","key":"2559_CR10","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne A, Arico M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728\u201338. https:\/\/doi.org\/10.1182\/blood-2017-06-788349.","journal-title":"Blood"},{"issue":"17","key":"2559_CR11","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam H, Horne A, Arico M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577\u201384. https:\/\/doi.org\/10.1182\/blood-2011-06-356261.","journal-title":"Blood"},{"issue":"23","key":"2559_CR12","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Rosee","year":"2019","unstructured":"La Rosee P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465\u201377. https:\/\/doi.org\/10.1182\/blood.2018894618.","journal-title":"Blood"},{"issue":"2","key":"2559_CR13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/curroncol29020097","volume":"29","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Lin Y, Bao Y, Jin Y, Ye X, Tan Y. Analysis of prognostic risk factors and establishment of prognostic scoring system for secondary adult hemophagocytic syndrome. Curr Oncol. 2022;29(2):1136\u201349. https:\/\/doi.org\/10.3390\/curroncol29020097.","journal-title":"Curr Oncol"},{"issue":"5","key":"2559_CR14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/bloodadvances.2022007953","volume":"7","author":"T Wimmer","year":"2023","unstructured":"Wimmer T, Mattes R, Stemmler HJ, Hauck F, Schulze-Koops H, Stecher SS, et al. sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study. Blood Adv. 2023;7(5):832\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2022007953.","journal-title":"Blood Adv"},{"issue":"1","key":"2559_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jaci.2023.07.023","volume":"153","author":"C Bloch","year":"2024","unstructured":"Bloch C, Jais JP, Gil M, Boubaya M, Lepelletier Y, Bader-Meunier B, et al. Severe adult hemophagocytic lymphohistiocytosis (HLHa) correlates with HLH-related gene variants. J Allergy Clin Immunol. 2024;153(1):256\u201364. https:\/\/doi.org\/10.1016\/j.jaci.2023.07.023.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2559_CR16","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","volume":"9","author":"A Setiadi","year":"2022","unstructured":"Setiadi A, Zoref-Lorenz A, Lee CY, Jordan MB, Chen LYC. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol. 2022;9(3):e217\u201327. https:\/\/doi.org\/10.1016\/S2352-3026(21)00366-5.","journal-title":"Lancet Haematol."},{"issue":"4","key":"2559_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.semarthrit.2015.07.004","volume":"45","author":"P Brito-Zeron","year":"2016","unstructured":"Brito-Zeron P, Bosch X, Perez-de-Lis M, Perez-Alvarez R, Fraile G, Gheitasi H, et al. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. Semin Arthritis Rheum. 2016;45(4):391\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.07.004.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2559_CR18","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/apa.15973","volume":"110","author":"S Imashuku","year":"2021","unstructured":"Imashuku S, Morimoto A, Ishii E. Virus-triggered secondary hemophagocytic lymphohistiocytosis. Acta Paediatr. 2021;110(10):2729\u201336. https:\/\/doi.org\/10.1111\/apa.15973.","journal-title":"Acta Paediatr"},{"issue":"11","key":"2559_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009944","volume":"15","author":"Q Shi","year":"2021","unstructured":"Shi Q, Huang M, Li X, Zheng X, Wang F, Zou Y, et al. Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by Leishmania infantum infection. PLoS Negl Trop Dis. 2021;15(11): e0009944. https:\/\/doi.org\/10.1371\/journal.pntd.0009944.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"2559_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.eimc.2020.04.012","volume":"39","author":"J Badiola","year":"2021","unstructured":"Badiola J, Munoz-Medina L, Callejas JL, Delgado-Garcia A, Jurado M, Hernandez-Quero J. Hemophagocytic lymphohistiocytosis associated with Leishmania: a hidden passenger in endemic areas. Enferm Infecc Microbiol Clin. 2021;39(4):188\u201391. https:\/\/doi.org\/10.1016\/j.eimc.2020.04.012.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"12","key":"2559_CR21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1473-3099(07)70290-6","volume":"7","author":"NG Rouphael","year":"2007","unstructured":"Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated with haemophagocytic syndrome. Lancet Infect Dis. 2007;7(12):814\u201322. https:\/\/doi.org\/10.1016\/S1473-3099(07)70290-6.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2559_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14787210.2020.1751611","volume":"18","author":"E Gianchecchi","year":"2020","unstructured":"Gianchecchi E, Montomoli E. The enemy at home: leishmaniasis in the Mediterranean basin, Italy on the focus. Expert Rev Anti Infect Ther. 2020;18(6):563\u201377. https:\/\/doi.org\/10.1080\/14787210.2020.1751611.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2559_CR23","doi-asserted-by":"publisher","first-page":"1210041","DOI":"10.3389\/fimmu.2023.1210041","volume":"14","author":"A Chinnici","year":"2023","unstructured":"Chinnici A, Beneforti L, Pegoraro F, Trambusti I, Tondo A, Favre C, et al. Approaching hemophagocytic lymphohistiocytosis Front Immunol. 2023;14:1210041. https:\/\/doi.org\/10.3389\/fimmu.2023.1210041.","journal-title":"Approaching hemophagocytic lymphohistiocytosis Front Immunol"},{"issue":"5","key":"2559_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4274\/balkanmedj.galenos.2022.2022-4-83","volume":"39","author":"AG Kacar","year":"2022","unstructured":"Kacar AG, Celkan TT. Hemophagocytic lymphohistiocytosis. Balkan Med J. 2022;39(5):309\u201317. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2022.2022-4-83.","journal-title":"Balkan Med J"},{"key":"2559_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fimmu.2014.00167","volume":"5","author":"E Sieni","year":"2014","unstructured":"Sieni E, Cetica V, Hackmann Y, Coniglio ML, Da Ros M, Ciambotti B, et al. Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning. Front Immunol. 2014;5:167. https:\/\/doi.org\/10.3389\/fimmu.2014.00167.","journal-title":"Front Immunol"},{"issue":"9","key":"2559_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/jmg.2009.075341","volume":"47","author":"V Cetica","year":"2010","unstructured":"Cetica V, Santoro A, Gilmour KC, Sieni E, Beutel K, Pende D, et al. STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5. J Med Genet. 2010;47(9):595\u2013600. https:\/\/doi.org\/10.1136\/jmg.2009.075341.","journal-title":"J Med Genet"},{"issue":"7","key":"2559_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068045","volume":"8","author":"M Arico","year":"2013","unstructured":"Arico M, Boggio E, Cetica V, Melensi M, Orilieri E, Clemente N, et al. Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome. PLoS ONE. 2013;8(7): e68045. https:\/\/doi.org\/10.1371\/journal.pone.0068045.","journal-title":"PLoS ONE"},{"issue":"7","key":"2559_CR28","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1182\/blood-2010-01-256099","volume":"116","author":"RA Marsh","year":"2010","unstructured":"Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010;116(7):1079\u201382. https:\/\/doi.org\/10.1182\/blood-2010-01-256099.","journal-title":"Blood"},{"issue":"5","key":"2559_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00277-013-1925-8","volume":"93","author":"T Tsuji","year":"2014","unstructured":"Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A high sIL-2R\/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 2014;93(5):821\u20136. https:\/\/doi.org\/10.1007\/s00277-013-1925-8.","journal-title":"Ann Hematol"},{"issue":"5","key":"2559_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1179\/1607845413Y.0000000084","volume":"18","author":"Z Wu","year":"2013","unstructured":"Wu Z, Zhou J, Wei X, Wang X, Li Y, Peng B, et al. The role of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) in immune thrombocytopenia. Hematology. 2013;18(5):295\u20139. https:\/\/doi.org\/10.1179\/1607845413Y.0000000084.","journal-title":"Hematology"},{"key":"2559_CR31","doi-asserted-by":"publisher","unstructured":"Raadsen M, Du Toit J, Langerak T, van Bussel B, van Gorp E, Goeijenbier M. Thrombocytopenia in Virus Infections. J Clin Med. 2021;10(4):877. https:\/\/doi.org\/10.3390\/jcm10040877.","DOI":"10.3390\/jcm10040877"},{"key":"2559_CR32","doi-asserted-by":"publisher","first-page":"205031212110367","DOI":"10.1177\/20503121211036787","volume":"9","author":"B Tarekegn","year":"2021","unstructured":"Tarekegn B, Tamene A. Clinical and laboratory profiles of visceral leishmaniasis among adult patients admitted to Felege Hiwot Hospital, Bahir Dar. Ethiopia SAGE Open Med. 2021;9:20503121211036788. https:\/\/doi.org\/10.1177\/20503121211036787.","journal-title":"Ethiopia SAGE Open Med"},{"key":"2559_CR33","doi-asserted-by":"publisher","first-page":"1210219","DOI":"10.3389\/fimmu.2023.1210219","volume":"14","author":"D Cox","year":"2023","unstructured":"Cox D. Sepsis - it is all about the platelets. Front Immunol. 2023;14:1210219. https:\/\/doi.org\/10.3389\/fimmu.2023.1210219.","journal-title":"Front Immunol"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02559-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02559-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02559-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:41:44Z","timestamp":1758721304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02559-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2559"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02559-z","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}